WO1997028797A1 - Procede de traitement et composition pharmaceutique - Google Patents

Procede de traitement et composition pharmaceutique Download PDF

Info

Publication number
WO1997028797A1
WO1997028797A1 PCT/US1997/001799 US9701799W WO9728797A1 WO 1997028797 A1 WO1997028797 A1 WO 1997028797A1 US 9701799 W US9701799 W US 9701799W WO 9728797 A1 WO9728797 A1 WO 9728797A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
loratadine
pharmaceutical formulation
sodium
leukotriene antagonist
Prior art date
Application number
PCT/US1997/001799
Other languages
English (en)
Inventor
Sven-Erik Dahlen
Edward M. Scolnick
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en
Priority to SK1056-98A priority Critical patent/SK105698A3/sk
Priority to NZ331160A priority patent/NZ331160A/xx
Priority to JP9528627A priority patent/JPH11504044A/ja
Priority to EP97905757A priority patent/EP1014972A4/fr
Priority to BR9707369A priority patent/BR9707369A/pt
Priority to EE9800234A priority patent/EE9800234A/xx
Priority to EA199800698A priority patent/EA199800698A1/ru
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to IL12544697A priority patent/IL125446A0/xx
Priority to AU22579/97A priority patent/AU732671B2/en
Priority to UA98084549A priority patent/UA59359C2/uk
Publication of WO1997028797A1 publication Critical patent/WO1997028797A1/fr
Priority to IS4805A priority patent/IS4805A/is
Priority to BG102669A priority patent/BG102669A/bg
Priority to NO983641A priority patent/NO983641D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • Loratadine is an antihistamine with H-receptor antagonist properties useful in the treatment of allergies and is described in U.S. Patent 4,282,233.
  • Leukotriene antagonists are known to be useful in the treatment of asthma, allergic reactions, and inflammation.
  • This invention is concerned with a method of treatment of asthma, allergy and inflammation by administration of an effective amount of loratadine and an effective amount of a leukotriene antagonist either by essentially concurrent administration or combined in a single pharmaceutical composition wherein the leukotriene antagonist is selected from:
  • the novel pharmaceutical composition of this invention comprises a combination of loratadine and a leukotriene antagonist selected from A, B, C, D and E, described above, as active ingredients, and optionally a pharmaeutically acceptable carrier suitable for enteral or parenteral administration.
  • the formulations may be in solid form, as for example tablets and capsules, or in liquid form, as for example, syrups, elixirs, emulsions and injectables.
  • excipients such as water, gelatin, lactose starches, magnesium stearate, talc, vegetable oils, benzyl alcohol, gums, polyalkylene glycols, and petroleum jelly.
  • a preferred formulation is mere fully described in the following Example.
  • the loratadine and leukotriene antagonist can be administered substantially concurrently as separate dosage forms or combined in the novel pharmaceutical formulation of this invention.
  • the preferred human oral dosage range is about 5 to 20 mg., loratadine, 1 to 3 times per day; preferably about 10 mg. once a day.
  • the human dosage range is also about 5 to 20 mg 1 to 3 times per day; preferably about 10 mg. once a day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ce procédé de traitement de l'asthme, de l'allergie et de l'inflammation consiste à traiter ces manifestations à l'aide d'un inhibiteur des leucotriènes, ainsi que de loratadine, par administration simultanée de ceux-ci, soit sous des doses séparées, soit sous des doses combinées en une seule formulation pharmaceutique.
PCT/US1997/001799 1996-02-08 1997-02-04 Procede de traitement et composition pharmaceutique WO1997028797A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU22579/97A AU732671B2 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composition
EA199800698A EA199800698A1 (ru) 1996-02-08 1997-02-04 Способ лечения и фармацевтическая композиция
JP9528627A JPH11504044A (ja) 1996-02-08 1997-02-04 治療方法及び医薬製剤
EP97905757A EP1014972A4 (fr) 1996-02-08 1997-02-04 Procede de traitement et composition pharmaceutique
BR9707369A BR9707369A (pt) 1996-02-08 1997-02-04 Formulação farmacéutica e processo para tratamento de asma de alergia e de inflamação em um paciente
EE9800234A EE9800234A (et) 1996-02-08 1997-02-04 Ravimeetod ja farmatseutiline kompositsioon
IL12544697A IL125446A0 (en) 1996-02-08 1997-02-04 Pharmaceutical composition for the treatment of asthma allergy and inflammation
SK1056-98A SK105698A3 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composion
NZ331160A NZ331160A (en) 1996-02-08 1997-02-04 use of loratadine and a leukotriene antagonist to treat asthma
UA98084549A UA59359C2 (uk) 1996-02-08 1997-04-02 Фармацевтична композиція та спосіб лікування астми, алергії та запалення у пацієнта
IS4805A IS4805A (is) 1996-02-08 1998-07-22 Aðferð til meðhöndlunar og lyfjasamsetning
BG102669A BG102669A (bg) 1996-02-08 1998-08-05 Метод за лечение и фармацевтичен състав
NO983641A NO983641D0 (no) 1996-02-08 1998-08-07 Fremgangsmåte til behandling og farmasöytisk preparat

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1132896P 1996-02-08 1996-02-08
US60/011,328 1996-02-08
GB9608927.1 1996-04-29
GBGB9608927.1A GB9608927D0 (en) 1996-04-29 1996-04-29 Method of treatment and pharmaceutical composition

Publications (1)

Publication Number Publication Date
WO1997028797A1 true WO1997028797A1 (fr) 1997-08-14

Family

ID=26309231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/001799 WO1997028797A1 (fr) 1996-02-08 1997-02-04 Procede de traitement et composition pharmaceutique

Country Status (19)

Country Link
EP (1) EP1014972A4 (fr)
JP (1) JPH11504044A (fr)
KR (1) KR19990082367A (fr)
CN (1) CN1210465A (fr)
AU (1) AU732671B2 (fr)
BG (1) BG102669A (fr)
BR (1) BR9707369A (fr)
CA (1) CA2245162A1 (fr)
CZ (1) CZ248798A3 (fr)
EE (1) EE9800234A (fr)
IL (1) IL125446A0 (fr)
IS (1) IS4805A (fr)
NO (1) NO983641D0 (fr)
NZ (1) NZ331160A (fr)
PL (1) PL328074A1 (fr)
SK (1) SK105698A3 (fr)
TR (1) TR199801511T2 (fr)
WO (1) WO1997028797A1 (fr)
YU (1) YU33298A (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025338A1 (fr) * 1997-11-14 1999-05-27 Astrazeneca Uk Limited Compositions pharmaceutiques contenant du zafirlukast
WO1999032125A1 (fr) * 1997-12-23 1999-07-01 Schering Corporation Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
WO2000006545A1 (fr) * 1998-07-27 2000-02-10 Schering Corporation Ligands d'affinite elevee pour recepteur de la nociceptine orl-1
WO2000015226A1 (fr) * 1998-09-10 2000-03-23 Schering Corporation Anti-histamines traitant la sinusite ou l'otite moyenne non infectieuse
WO2000057880A1 (fr) * 1999-03-29 2000-10-05 Schering Corporation Procedes et compositions pour traiter des troubles allergiques et troubles associes au moyen de descarboethoxyloratadine fluoree
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
WO2001060407A2 (fr) * 2000-02-17 2001-08-23 Viatris Gmbh & Co. Kg Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite
JP2002511425A (ja) * 1998-04-14 2002-04-16 セプラコア インコーポレーテッド ロイコトリエン阻害剤と共にセチリジンを用いる、ロイコトリエン阻害に応答性の症状を治療するための方法および組成物
WO2002036124A2 (fr) * 2000-10-30 2002-05-10 Schering Corporation Procede de traitement
WO2002080916A1 (fr) * 2001-04-03 2002-10-17 Kaura Sita R Traitement d'affection respiratoire et composition a cet effet
WO2004087095A2 (fr) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositif osmotique contenant du zafirlukast et un antagoniste h1
WO2005037245A2 (fr) * 2003-10-21 2005-04-28 Direct-Haler A/S Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
WO2005089748A1 (fr) * 2004-03-17 2005-09-29 Pfizer Limited Combinaison pour traitement de maladies inflammatoires
WO2006047427A1 (fr) 2004-10-25 2006-05-04 Schering Corporation Antagonistes des recepteurs m1 et/ou m3 combines a d'autres agents actifs pour le traitement de maladies respiratoires
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
WO2010021607A3 (fr) * 2008-08-22 2010-06-03 Mahmut Bilgic Préparation pharmaceutique
WO2010147947A2 (fr) 2009-06-16 2010-12-23 Schering Corporation Nouveaux [3,2-c] hétéroaryl stéroïdes en tant qu'agonistes des récepteurs glucocorticoïdes, compositions et utilisations de ceux-ci
WO2020143744A1 (fr) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540191B1 (ko) * 2014-02-24 2015-07-28 성균관대학교산학협력단 로라타딘을 포함하는 항염증용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233A (en) * 1980-06-19 1981-08-04 Schering Corporation Antihistaminic 11-(4-piperidylidene)-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridines
US4847275A (en) * 1984-08-20 1989-07-11 Ono Pharmaceutical Co., Ltd. (Fused) benz (thio) amides
US5030643A (en) * 1985-04-17 1991-07-09 Ici Americas Inc. Heterocyclic amide derivatives and use
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233A (en) * 1980-06-19 1981-08-04 Schering Corporation Antihistaminic 11-(4-piperidylidene)-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridines
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4847275A (en) * 1984-08-20 1989-07-11 Ono Pharmaceutical Co., Ltd. (Fused) benz (thio) amides
US5030643A (en) * 1985-04-17 1991-07-09 Ici Americas Inc. Heterocyclic amide derivatives and use
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1014972A4 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7214684B2 (en) 1994-12-30 2007-05-08 Sepracor Inc. Methods for the treatment of allergic rhinitis
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
WO1999025338A1 (fr) * 1997-11-14 1999-05-27 Astrazeneca Uk Limited Compositions pharmaceutiques contenant du zafirlukast
US6333361B1 (en) 1997-11-14 2001-12-25 Zeneca Limited Pharmaceutical composition containing zafirlukast
JP2001526232A (ja) * 1997-12-23 2001-12-18 シェーリング コーポレイション 少なくとも一つのロイコトリエンアンタゴニストおよび少なくとも一つの抗ヒスタミン剤を含有する呼吸器および皮膚疾患処置のための組成物
WO1999032125A1 (fr) * 1997-12-23 1999-07-01 Schering Corporation Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
US6509353B1 (en) 1998-04-14 2003-01-21 Sepracor Inc. Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US8404715B2 (en) 1998-04-14 2013-03-26 Sunovion Pharmaceuticals Inc. Methods and compositions using racemic, (R)-, and (S)-fexofenadine in combination with leukotriene inhibitors
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6790849B2 (en) 1998-04-14 2004-09-14 Sepracor Inc. Methods and compositions using optically pure (-) cetirizine in combination with leukotriene inhibitors or decongestants
JP2002511426A (ja) * 1998-04-14 2002-04-16 セプラコア インコーポレーテッド ロイコトリエン阻害剤と共にターフェナジン代謝産物を用いる方法および組成物
US6372197B1 (en) 1998-04-14 2002-04-16 Sepracor Inc. Methods and compositions using norastemizole in combination with leukotriene inhibitors
JP2002511425A (ja) * 1998-04-14 2002-04-16 セプラコア インコーポレーテッド ロイコトリエン阻害剤と共にセチリジンを用いる、ロイコトリエン阻害に応答性の症状を治療するための方法および組成物
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US7094784B2 (en) 1998-07-27 2006-08-22 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
WO2000006545A1 (fr) * 1998-07-27 2000-02-10 Schering Corporation Ligands d'affinite elevee pour recepteur de la nociceptine orl-1
US6455527B2 (en) 1998-07-27 2002-09-24 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6716846B2 (en) 1998-07-27 2004-04-06 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
WO2000015226A1 (fr) * 1998-09-10 2000-03-23 Schering Corporation Anti-histamines traitant la sinusite ou l'otite moyenne non infectieuse
WO2000057880A1 (fr) * 1999-03-29 2000-10-05 Schering Corporation Procedes et compositions pour traiter des troubles allergiques et troubles associes au moyen de descarboethoxyloratadine fluoree
AU781177B2 (en) * 2000-02-17 2005-05-12 Meda Pharma Gmbh & Co. Kg Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
WO2001060407A3 (fr) * 2000-02-17 2002-03-07 Asta Medica Ag Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite
US6436924B2 (en) 2000-02-17 2002-08-20 Asta Medica Ag Antihistamine leukotriene combinations
WO2001060407A2 (fr) * 2000-02-17 2001-08-23 Viatris Gmbh & Co. Kg Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite
WO2002036124A3 (fr) * 2000-10-30 2003-02-13 Schering Corp Procede de traitement
WO2002036124A2 (fr) * 2000-10-30 2002-05-10 Schering Corporation Procede de traitement
WO2002080916A1 (fr) * 2001-04-03 2002-10-17 Kaura Sita R Traitement d'affection respiratoire et composition a cet effet
EP1383500A4 (fr) * 2001-04-03 2008-11-05 Sita R Kaura Traitement d'affection respiratoire et composition a cet effet
EP1383500A1 (fr) * 2001-04-03 2004-01-28 Sita R. Kaura Traitement d'affection respiratoire et composition a cet effet
WO2004087095A2 (fr) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositif osmotique contenant du zafirlukast et un antagoniste h1
WO2004087095A3 (fr) * 2003-03-31 2005-07-21 Osmotica Costa Rica Sa Dispositif osmotique contenant du zafirlukast et un antagoniste h1
WO2005037245A2 (fr) * 2003-10-21 2005-04-28 Direct-Haler A/S Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
WO2005037245A3 (fr) * 2003-10-21 2005-08-11 Direct Haler As Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
WO2005089748A1 (fr) * 2004-03-17 2005-09-29 Pfizer Limited Combinaison pour traitement de maladies inflammatoires
WO2006047427A1 (fr) 2004-10-25 2006-05-04 Schering Corporation Antagonistes des recepteurs m1 et/ou m3 combines a d'autres agents actifs pour le traitement de maladies respiratoires
WO2010021607A3 (fr) * 2008-08-22 2010-06-03 Mahmut Bilgic Préparation pharmaceutique
WO2010147947A2 (fr) 2009-06-16 2010-12-23 Schering Corporation Nouveaux [3,2-c] hétéroaryl stéroïdes en tant qu'agonistes des récepteurs glucocorticoïdes, compositions et utilisations de ceux-ci
WO2020143744A1 (fr) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes

Also Published As

Publication number Publication date
KR19990082367A (ko) 1999-11-25
TR199801511T2 (xx) 1998-10-21
EE9800234A (et) 1998-12-15
IL125446A0 (en) 1999-03-12
NO983641L (no) 1998-08-07
SK105698A3 (en) 1999-05-07
AU2257997A (en) 1997-08-28
JPH11504044A (ja) 1999-04-06
CA2245162A1 (fr) 1997-08-14
CZ248798A3 (cs) 1999-01-13
EP1014972A4 (fr) 2004-12-08
YU33298A (en) 1999-11-22
BG102669A (bg) 1999-04-30
CN1210465A (zh) 1999-03-10
NO983641D0 (no) 1998-08-07
AU732671B2 (en) 2001-04-26
PL328074A1 (en) 1999-01-04
EP1014972A1 (fr) 2000-07-05
BR9707369A (pt) 1999-07-20
NZ331160A (en) 2000-07-28
IS4805A (is) 1998-07-22

Similar Documents

Publication Publication Date Title
WO1997028797A1 (fr) Procede de traitement et composition pharmaceutique
CA2315721C (fr) Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
AU781177B2 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
EP2799071B1 (fr) Lévocétirizine et montélukast pour le traitement de la grippe et le rhume
CA2328073A1 (fr) Methodes, et compositions afferentes, d'utilisation de cetirizine en combinaison avec des inhibiteurs de leucotriene pour traiter des troubles consecutifs a l'inhibition de leucotriene
US20120149730A1 (en) Methods and compositions using racemic, (r)-, and (s)-fexofenadine in combination with leukotriene inhibitors
EP2762141A1 (fr) Produit pharmaceutique thérapeutique contre la rhinite allergique comportant un antagoniste de pgd2 et un antagoniste d'histamine
CA2427814C (fr) Combinaison d'un inhibiteur de pde4 et d'un antagoniste des leucotrienes dans le traitement de troubles respiratoires et bronchiques
US6372197B1 (en) Methods and compositions using norastemizole in combination with leukotriene inhibitors
US20070275996A1 (en) Use of Statins For The Treatment Of Metabolic Syndrome
EP2121021A2 (fr) Procédés pour traiter une congestion nasale
CN114569608A (zh) Aerd/哮喘中的血栓烷受体拮抗剂
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物
US20040048890A1 (en) Compositions comprising a leukotriene inhibitor and a decongestant
WO2001003701A1 (fr) Composition orale contenant du budesonide en tant que premier principe actif et un antibiotique en tant que second principe actif, utilisee pour les troubles intestinaux, notamment la maladie de crohn
WO2001003703A1 (fr) Composition orale comportant en tant que premier principe actif un rofleponide et en tant que second ingredient un antibiotique, destinee a traiter des troubles intestinaux tels que la maladie de crohn
WO2010116127A1 (fr) Combinaison de cétirizine et d'acide méfénamique pour le traitement d'exacerbations de l'asthme

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192149.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2245162

Country of ref document: CA

Ref document number: 2245162

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997905757

Country of ref document: EP

Ref document number: 331160

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 105698

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 1997 528627

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998/01511

Country of ref document: TR

Ref document number: P-332/98

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/006421

Country of ref document: MX

Ref document number: PV1998-2487

Country of ref document: CZ

Ref document number: 1019980706097

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 199800698

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: PV1998-2487

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980706097

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997905757

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019980706097

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: PV1998-2487

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1997905757

Country of ref document: EP